What is the diagnosis and management for a patient with increased poikilocytosis, anisocytosis, and burr cells?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diagnosis and Management of Increased Poikilocytosis, Anisocytosis, and Burr Cells

The presence of increased poikilocytosis, anisocytosis, and burr cells on peripheral blood smear strongly suggests a myelodysplastic syndrome (MDS) and requires bone marrow examination with cytogenetic analysis for definitive diagnosis and risk stratification. 1

Diagnostic Approach

Initial Evaluation

  • Complete blood count with red cell indices
  • Comprehensive peripheral blood smear examination
  • Reticulocyte count
  • Serum ferritin, transferrin saturation
  • C-reactive protein (CRP)
  • Lactate dehydrogenase (LDH)
  • Haptoglobin
  • Vitamin B12 and folate levels

Peripheral Blood Findings

  • Anisocytosis: variation in red cell size
  • Poikilocytosis: variation in red cell shape
  • Burr cells (echinocytes): spiculated red cells with short, evenly spaced projections
  • Additional findings to look for:
    • Dimorphic erythrocytes
    • Hypochromasia or polychromasia
    • Basophilic stippling
    • Tear drop cells
    • Presence of nucleated erythroid precursors 1, 2

Mandatory Diagnostic Tests

  1. Bone marrow aspirate and biopsy to evaluate:

    • Cellularity
    • Dysplasia in one or more hematopoietic cell lines
    • Blast percentage
    • Ring sideroblasts
    • Fibrosis 1
  2. Cytogenetic analysis:

    • Detection of acquired clonal chromosomal abnormalities
    • Standard karyotype has highest prognostic value in MDS 1

Recommended Additional Tests

  • Fluorescence in situ hybridization (FISH) if standard cytogenetics fails
  • Flow cytometry immunophenotyping to detect abnormalities in various cell compartments
  • Molecular testing for mutations in DNMT3A, ASXL1, TET2, JAK2, and TP53 genes 1, 2

Differential Diagnosis

Myelodysplastic Syndromes (MDS)

  • Primary consideration with peripheral blood showing anisocytosis, poikilocytosis, and dysplastic features
  • Characterized by ineffective hematopoiesis, peripheral cytopenias, and risk of progression to acute myeloid leukemia 1

Pyruvate Kinase Deficiency

  • Can present with anisocytosis and poikilocytosis
  • Usually has echinocytes (3-30%), particularly after splenectomy
  • Characterized by chronic hemolysis with increased reticulocyte count, LDH, and bilirubin 1

Iron Deficiency Anemia

  • Can present with anisocytosis and poikilocytosis
  • Typically has low serum ferritin (<30 μg/L without inflammation)
  • With inflammation, ferritin up to 100 μg/L may still indicate iron deficiency 1

Other Conditions

  • Hemolytic anemias
  • Thalassemias
  • Drug-induced ineffective erythropoiesis (e.g., chemotherapy agents) 3
  • Advanced malignancy 4

Management Strategy

For Confirmed MDS

  1. Risk stratification using the International Prognostic Scoring System-Revised (IPSS-R)

    • Based on cytogenetics, blast percentage, and cytopenias
  2. Treatment based on risk category:

    • Low-risk MDS:

      • Erythropoiesis-stimulating agents if erythropoietin level <500 mU/mL
      • Red blood cell transfusions for symptomatic anemia
      • Iron chelation therapy for transfusion-dependent patients
    • High-risk MDS:

      • Hypomethylating agents (azacitidine or decitabine)
      • Consideration for allogeneic stem cell transplantation in eligible patients 1, 2

For Other Diagnoses

  • Treat the underlying cause (iron deficiency, vitamin deficiencies, etc.)
  • For pyruvate kinase deficiency: supportive care with transfusions, splenectomy in severe cases, monitoring for complications like iron overload and gallstones 1

Monitoring and Follow-up

  • Regular complete blood counts
  • Periodic bone marrow examinations for MDS patients to monitor disease progression
  • Monitor for iron overload in transfusion-dependent patients
  • Surveillance for transformation to acute myeloid leukemia in MDS patients

Pitfalls and Caveats

  • Burr cells (echinocytes) can be artifactual due to prolonged storage of blood samples or high EDTA concentration
  • Anisocytosis and poikilocytosis are nonspecific findings and can be seen in various hematologic disorders
  • MDS diagnosis requires exclusion of other causes of cytopenias and dysplasia, including vitamin deficiencies, medications, toxins, and other hematologic disorders
  • Cytogenetic abnormalities are crucial for diagnosis and prognosis but may be absent in up to 20% of MDS cases 1
  • Splenectomy should be approached with caution in hematologic disorders due to risk of thrombotic complications 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Hematological Disorders

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Poikilocytosis in cancer patients.

California medicine, 1967

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.